PMID- 34295178
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 14
DP  - 2021
TI  - Identification and Validation of Biglycan as Prognosis and Therapy Markers for 
      Patients with Stomach Adenocarcinoma.
PG  - 3497-3509
LID - 10.2147/IJGM.S321641 [doi]
AB  - OBJECTIVE: Previous studies have confirmed the biglycan (BGN) as a core gene in 
      stomach adenocarcinoma (STAD). Present study aimed at conducting further 
      investigations to reveal the potential function of BGN in STAD. METHODS: The mRNA 
      and protein expressions of BGN in STAD were firstly evaluated, followed by immune 
      infiltration analyses. The influence of BGN expression on the overall survival of 
      STAD patients was subsequently analyzed, and a restrict survival analysis was 
      performed as well. The protein-protein interaction (PPI) network analysis on the 
      co-expressed genes with BGN was finally adopted to obtain the most important 
      module in the whole network, and significant Kyoto Encyclopedia of Genes and 
      Genomes (KEGG) pathway associated with hub genes within the main module was 
      further predicted. RESULTS: (1) We verified the mRNA high expression of BGN in 
      STAD (all P<0.05), and higher expression was observed in patients with stage 4 
      (P<0.001) and grade 3 (P<0.001). The BGN protein was mainly localized to the 
      golgi apparatus, and protein expression displayed an individual difference. (2) 
      Immune infiltration analysis showed the strongest correlation between BGN 
      expression and abundance of natural killer cell (P<0.001), Transforming Growth 
      Factor beta 1 (TGFB1) (P<0.001), TNF Receptor Superfamily Member 4 (TNFRSF4) 
      (P<0.001) and C-X-C Motif Chemokine Ligand 12 (CXCL12) (P<0.001) in STAD. BGN 
      expression was also correlated to immune subtypes (P=0.0347) and molecular 
      subtypes (P=0.0263) in STAD. (3) High expression of BGN shortened the overall 
      survival time of STAD patients (all P<0.01). The influence of BGN expression on 
      the prognosis was statistically affected by several clinical phenotypes and 
      cohorts of patients. Cox regression showed that BGN can be considered as a 
      prognostic predictor of STAD (P<0.05). (4) Pathway analysis indicated that BGN 
      possibly participated in ECM-receptor interaction, focal adhesion, human 
      papillomavirus infection and PI3K-Akt signaling pathway (all P<0.001). 
      CONCLUSION: BGN was highly expressed in STAD, implying a poor prognosis of 
      patients. Relevant signal pathways associated with BGN were distinguished as 
      well. BGN could be used as a potential therapeutic biomarker for STAD.
CI  - (c) 2021 Shao et al.
FAU - Shao, Changming
AU  - Shao C
AD  - Department of Vascular Surgery, The Second Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, 310000, Zhejiang, People's Republic of 
      China.
FAU - Cheng, Chunfa
AU  - Cheng C
AD  - Department of Vascular Surgery, The First People's Hospital of Yuhang District, 
      Hangzhou, 311100, Zhejiang, People's Republic of China.
FAU - Shao, Qinshu
AU  - Shao Q
AD  - Department of General Surgery, Zhejiang Provincial People's Hospital, Hangzhou, 
      310009, Zhejiang, People's Republic of China.
FAU - Chen, Bing
AU  - Chen B
AD  - Department of Vascular Surgery, The Second Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, 310000, Zhejiang, People's Republic of 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210715
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC8290488
OTO - NOTNLM
OT  - biglycan
OT  - high expression
OT  - immune infiltration
OT  - prognosis
OT  - stomach adenocarcinoma
COIS- The authors have no conflicts of interest in this work.
EDAT- 2021/07/24 06:00
MHDA- 2021/07/24 06:01
PMCR- 2021/07/15
CRDT- 2021/07/23 06:45
PHST- 2021/05/26 00:00 [received]
PHST- 2021/06/28 00:00 [accepted]
PHST- 2021/07/23 06:45 [entrez]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2021/07/24 06:01 [medline]
PHST- 2021/07/15 00:00 [pmc-release]
AID - 321641 [pii]
AID - 10.2147/IJGM.S321641 [doi]
PST - epublish
SO  - Int J Gen Med. 2021 Jul 15;14:3497-3509. doi: 10.2147/IJGM.S321641. eCollection 
      2021.